How many times can a person get shingles?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How Many Times Can a Person Get Shingles?

A person can get shingles multiple times, though recurrence is uncommon in immunocompetent individuals, occurring in approximately 1.2-9.6% of people after an initial episode, with immunocompromised patients experiencing substantially higher recurrence rates of 0.0-18.2%. 1

Understanding Shingles Recurrence Rates

General Population Risk

  • Immunocompetent individuals have a relatively low risk of recurrence, with incidence rates ranging from 1.7-16.6 cases per 1000 person-years following an initial shingles episode 1
  • Approximately 6% of individuals may experience a second attack of shingles, typically occurring several decades after the first episode 2
  • The traditional teaching that shingles occurs only once is incorrect—recurrence is well-documented, though less common than initial episodes 1

Immunocompromised Population Risk

  • Immunocompromised patients face dramatically higher recurrence rates, with incidence rates of 17.0-55 cases per 1000 person-years 1
  • HIV-infected individuals and other immunocompromised hosts cannot have "quite infrequent" recurrences, with some developing chronic or recurrent episodes 3
  • Recurrence in immunocompromised patients is generally uncommon but occurs more frequently than in healthy individuals 4

Key Risk Factors for Recurrence

Patient-Specific Factors

  • Female sex is associated with increased recurrence risk 1
  • Family history of shingles predisposes to recurrence 1
  • Advanced age, though primarily a risk factor for initial episodes, may influence recurrence patterns 1

Medical Comorbidities

  • Diabetes mellitus increases recurrence risk 1
  • Immunosuppressive conditions including HIV infection, malignancies, and use of immunosuppressant medications substantially elevate recurrence rates 3, 1
  • Long-lasting pain after the initial episode may predict higher recurrence risk 1
  • Herpes zoster ophthalmicus (eye involvement) may predispose to future episodes 1

Clinical Implications

No Upper Limit on Episodes

  • There is no defined maximum number of times a person can develop shingles 1
  • Each episode represents reactivation of latent varicella-zoster virus from dorsal root or trigeminal ganglia 5
  • The virus remains latent in neuronal ganglia after primary varicella infection, creating lifelong potential for reactivation 6

Prevention Strategies After Initial Episode

Vaccination remains critical even after having shingles:

  • The recombinant zoster vaccine (Shingrix) is recommended for all adults aged 50 years and older, regardless of prior herpes zoster episodes 7, 4
  • Vaccination should be considered after recovery from an acute episode to prevent future recurrences 7

Suppressive antiviral therapy for frequent recurrences:

  • Daily acyclovir 400 mg orally twice daily is recommended for patients with frequent or severe recurrences, with documented safety for up to 6 years of continuous use 4
  • Alternative options include famciclovir 250 mg orally twice daily or valacyclovir 250-1000 mg daily, both documented as safe for up to 1 year 4
  • Consider discontinuing suppressive therapy after 1 year to reassess recurrence rate 4

Common Pitfalls to Avoid

  • Do not assume a patient cannot get shingles again after one episode—this outdated belief delays appropriate diagnosis and treatment of recurrent episodes 2, 1
  • Do not withhold vaccination from patients with prior shingles history—they remain at risk for recurrence and should receive Shingrix 7, 4
  • Do not use inadequate dosing for suppressive therapy in patients with very frequent recurrences—standard suppressive doses are required 4
  • Do not overlook immunocompromised status as a major risk factor requiring heightened vigilance for recurrence 1

References

Research

Management of herpes zoster (shingles) and postherpetic neuralgia.

Expert opinion on pharmacotherapy, 2004

Guideline

Preventing Shingles Recurrence

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Shingles (Herpes Zoster) and Post-herpetic Neuralgia.

Current treatment options in neurology, 2001

Guideline

Management of Herpes Zoster

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.